Sign Out
Hypersensitivity to eletriptan hydrobromide or to any of the excipients.
Patients with severe hepatic impairment.
As with other 5-hydroxytryptamine type 1 (5-HT1) receptor agonists, the following contraindications are based on the pharmacodynamic properties of eletriptan: Patients with uncontrolled hypertension.
Patients with confirmed coronary heart disease, including ischaemic heart disease (angina pectoris, previous myocardial infarction or confirmed silent ischaemia).
Patients with coronary artery vasospasm, objective or subjective symptoms of ischaemic heart disease or Prinzmetal’s angina.
Patients with peripheral vascular disease.
Patients with a history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA).
Administration of ergotamine, or derivatives of ergotamine (including methysergide) within 24 hours before or after treatment with eletriptan (see Interactions).
Concomitant administration of other 5-HT1 receptor agonists.
Continue with Google